This article contains a systematic review of the main developments that have occurred in the area of male hypogonadism between the publication of the Endocrine Society Guidelines of 2010 and 2018 and after 2018.
HamiltonJB. Treatment of sexual UNDERDEVELOPMENT with synthetic male hormone SUBSTANCE1. Endocrinology1937;21:649–54.doi:10.1210/endo-21-5-649
2.
NguyenCP, HirschMS, MoenyD, . Testosterone and “Age-Related Hypogonadism” — FDA Concerns. N Engl J Med2015;373:689–91.doi:10.1056/NEJMp1506632
3.
SnyderPJ, PeacheyH, BerlinJA, . Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab2000;85:2670–7.doi:10.1210/jc.85.8.2670
4.
KatznelsonL, FinkelsteinJS, SchoenfeldDA, . Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab1996;81:4358–65.
5.
SeftelAD, MackRJ, SecrestAR, . Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl2004;25:963–72.doi:10.1002/j.1939-4640.2004.tb03169.x
6.
PaduchDA, PolzerPK, NiX, . Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab2015;100:2956–62.doi:10.1210/jc.2014-4434
7.
SnyderPJ, BhasinS, CunninghamGR, . Effects of testosterone treatment in older men. N Engl J Med2016;374:611–24.doi:10.1056/NEJMoa1506119
8.
BrockG, HeiselmanD, MaggiM, . Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. J Urol2016;195:699–705.doi:10.1016/j.juro.2015.10.083
9.
YeapBB, GrossmannM, McLachlanRI, . Endocrine Society of Australia position statement on male hypogonadism (Part 2): treatment and therapeutic considerations. Med J Aust2016;205:228–31.doi:10.5694/mja16.00448
10.
BhasinS, BritoJP, CunninghamGR, . Testosterone therapy in men with hypogonadism: an endocrine Society* clinical practice guideline. J Clin Endocrinol Metab2018;103:1715–44.doi:10.1210/jc.2018-00229
11.
BhasinS, CunninghamGR, HayesFJ, . Testosterone therapy in men with androgen deficiency syndromes: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab2010;95:2536–59.doi:10.1210/jc.2009-2354
12.
LaytonJB, LiD, MeierCR, . Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab2014;99:835–42.doi:10.1210/jc.2013-3570
13.
WangC, NieschlagE, SwerdloffR, . Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl2009;32:1–10.doi:10.1111/j.1365-2605.2008.00924.x
14.
HuhtaniemiI. Late-Onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl2014;16:192–202.doi:10.4103/1008-682X.122336
15.
KheraM, BroderickGA, CarsonCC, . Adult-Onset hypogonadism. Mayo Clin Proc2016;91:908–26.doi:10.1016/j.mayocp.2016.04.022
16.
MannaPR, StoccoDM. Regulation of the steroidogenic acute regulatory protein expression: functional and physiological consequences. Curr Drug Targets Immune Endocr Metabol Disord2005;5:93–108.doi:10.2174/1568008053174714
17.
LejeuneH, SanchezP, ChuzelF, . Time-Course effects of human recombinant luteinizing hormone on porcine Leydig cell specific differentiated functions. Mol Cell Endocrinol1998;144:59–69.doi:10.1016/S0303-7207(98)00153-1
18.
HerbisonAE, TheodosisDT. Immunocytochemical identification of oestrogen receptors in preoptic neurones containing calcitonin gene-related peptide in the male and female rat. Neuroendocrinology1992;56:761–4.doi:10.1159/000126304
19.
SeminaraSB, MessagerS, ChatzidakiEE, . The GPR54 Gene as a Regulator of Puberty. N Engl J Med2003;349:1614–27.doi:10.1056/NEJMoa035322
20.
de RouxN, GeninE, CarelJ-C, . Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A2003;100:10972–6.doi:10.1073/pnas.1834399100
21.
UenoyamaY, InoueN, PhengV, . Ultrastructural evidence of kisspeptin-gonadotrophin-releasing hormone (GnRH) interaction in the median eminence of female rats: implication of axo-axonal regulation of GnRH release. J Neuroendocrinol2011;23:863–70.doi:10.1111/j.1365-2826.2011.02199.x
22.
LehmanMN, CoolenLM, GoodmanRL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology2010;151:3479–89.doi:10.1210/en.2010-0022
23.
TopalogluAK, ReimannF, GucluM, . TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet2009;41:354–8.doi:10.1038/ng.306
24.
YoungJ, GeorgeJT, TelloJA, . Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications. Neuroendocrinology2013;97:193–202.doi:10.1159/000336376
25.
PitteloudN, DwyerAA, DeCruzS, . Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab2008;93:784–91.doi:10.1210/jc.2007-2156
26.
O'HaraL, CurleyM, Tedim FerreiraM, . Pituitary androgen receptor signalling regulates prolactin but not gonadotrophins in the male mouse. PLoS One2015;10:e0121657.doi:10.1371/journal.pone.0121657
RochiraV, CaraniC. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol2009;5:559–68.doi:10.1038/nrendo.2009.176
29.
SmithEP, BoydJ, FrankGR, . Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med1994;331:1056–61.doi:10.1056/NEJM199410203311604
30.
HayesFJ, DeCruzS, SeminaraSB, . Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. J Clin Endocrinol Metab2001;86:53–8.doi:10.1210/jcem.86.1.7101
SmithJT, CunninghamMJ, RissmanEF, . Regulation of Kiss1 Gene Expression in the Brain of the Female Mouse. Endocrinology2005;146:3686–92.doi:10.1210/en.2005-0488
33.
NavarroVM, GottschML, WuM, . Regulation of NKB pathways and their roles in the control of KISS1 neurons in the arcuate nucleus of the male mouse. Endocrinology2011;152:4265–75.doi:10.1210/en.2011-1143
34.
HuhtaniemiIT, WarrenDW, CattKJ. Functional maturation of rat testis Leydig cells. Ann N Y Acad Sci1984;438:283–303.doi:10.1111/j.1749-6632.1984.tb38293.x
35.
HuhtaniemiI, PelliniemiLJ. Fetal Leydig cells: cellular origin, morphology, life span, and special functional features. Exp Biol Med1992;201:125–40.doi:10.3181/00379727-201-43493
36.
ReyesFI, BoroditskyRS, WinterJSD, . Studies on human sexual development. II. Fetal and maternal serum gonadotropin and sex steroid concentrations. J Clin Endocrinol Metab1974;38:612–7.doi:10.1210/jcem-38-4-612
37.
O'ShaughnessyPJ, FowlerPA. Endocrinology of the mammalian fetal testis. Reproduction2011;141:37–46.doi:10.1530/REP-10-0365
38.
MulchaheyJJ, DiblasioAM, MartinMC, . Hormone production and peptide regulation of the human fetal pituitary Gland*. Endocr Rev1987;8:406–25.doi:10.1210/edrv-8-4-406
39.
WeissJ, AxelrodL, WhitcombRW, . Hypogonadism caused by a single amino acid substitution in the β subunit of luteinizing hormone. N Engl J Med1992;326:179–83.doi:10.1056/NEJM199201163260306
40.
LatronicoAC, ArnholdIJP. Inactivating mutations of LH and FSH receptors–from genotype to phenotype. Pediatr Endocrinol Rev2006;4:28–31.
BayK, MainKM, ToppariJ, . Testicular descent: INSL3, testosterone, genes and the intrauterine milieu. Nat Rev Urol2011;8:187–96.doi:10.1038/nrurol.2011.23
43.
CorbierP, DehenninL, CastanierM, . Sex differences in serum luteinizing hormone and testosterone in the human neonate during the first few hours after Birth*. J Clin Endocrinol Metab1990;71:1344–8.doi:10.1210/jcem-71-5-1344
44.
BoasM, BoisenKA, VirtanenHE, . Postnatal penile length and growth rate correlate to serum testosterone levels: a longitudinal study of 1962 normal boys. Eur J Endocrinol2006;154:125–9.doi:10.1530/eje.1.02066
45.
KuijperEAM, van KootenJ, VerbekeJIML, . Ultrasonographically measured testicular volumes in 0- to 6-year-old boys. Hum Reprod2008;23:792–6.doi:10.1093/humrep/den021
46.
GoldmanAL, BhasinS, WuFCW, . A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev2017;38:302–24.doi:10.1210/er.2017-00025
47.
ZakharovMN, BhasinS, TravisonTG, . A multi-step, dynamic allosteric model of testosterone's binding to sex hormone binding globulin. Mol Cell Endocrinol2015;399:190–200.doi:10.1016/j.mce.2014.09.001
48.
MendelCM. The free hormone hypothesis: a physiologically based mathematical Model*. Endocr Rev1989;10:232–74.doi:10.1210/edrv-10-3-232
DamassaDA, LinTM, SonnenscheinC, . Biological effects of sex hormone-binding globulin on androgen-induced proliferation and androgen metabolism in LNCaP prostate Cells*. Endocrinology1991;129:75–84.doi:10.1210/endo-129-1-75
51.
GiorgiEP, SteinWD. The transport of steroids into animal cells in culture. Endocrinology1981;108:688–97.doi:10.1210/endo-108-2-688
52.
LasnitzkiI, FranklinHR. The influence of serum on uptake, conversion and action of testosterone in rat prostate glands in organ culture. J Endocrinol1972;54:333–NP.doi:10.1677/joe.0.0540333
53.
VosMJ, MijnhoutGS, RondeelJMM, . Sex hormone binding globulin deficiency due to a homozygous missense mutation. J Clin Endocrinol Metab2014;99:E1798–802.doi:10.1210/jc.2014-2055
54.
van den BeldAW, de JongFH, GrobbeeDE, . Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab2000;85:3276–82.
55.
AntonioL, WuFCW, O'NeillTW, . Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab2016;101:2647–57.doi:10.1210/jc.2015-4106
56.
RosnerW. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent Advances*. Endocr Rev1990;11:80–91.doi:10.1210/edrv-11-1-80
57.
WickhamEP, EwensKG, LegroRS, . Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab2011;96:E719–27.doi:10.1210/jc.2010-1842
58.
HammondGL, RuokonenA, KontturiM, . The simultaneous radioimmunoassay of seven steroids in human spermatic and peripheral venous blood. J Clin Endocrinol Metab1977;45:16–24.doi:10.1210/jcem-45-1-16
59.
SanfordEJ, PaulsonDF, RohnerTJ, . The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J Urol1977;118:1019–21.doi:10.1016/S0022-5347(17)58283-X
60.
BardinC, CatterallJ. Testosterone: a major determinant of extragenital sexual dimorphism. Science1981;211:1285–94.doi:10.1126/science.7010603
61.
LiaoS, LiangT, FangS, . Steroid structure and androgenic activity. specificities involved in the receptor binding and nuclear retention of various androgens. J Biol Chem1973;248:6154–62.
62.
DeslypereJ-P, YoungM, WilsonJD, . Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol1992;88:15–22.doi:10.1016/0303-7207(92)90004-P
63.
GrinoPB, GriffinJE, WilsonJD. Testosterone at high concentrations interacts with the human androgen receptor similarly to Dihydrotestosterone*. Endocrinology1990;126:1165–72.doi:10.1210/endo-126-2-1165
64.
BhasinS, TravisonTG, StorerTW, . Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production. JAMA2012;307:931–9.doi:10.1001/jama.2012.227
65.
Imperato-McGinleyJ, ZhuY-S. Androgens and male physiology the syndrome of 5α-reductase-2 deficiency. Mol Cell Endocrinol2002;198:51–9.doi:10.1016/S0303-7207(02)00368-4
66.
SartoriusG, SpasevskaS, IdanA, . Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol2012;77:755–63.doi:10.1111/j.1365-2265.2012.04432.x
67.
YeapBB, AlmeidaOP, HydeZ, . Healthier lifestyle predicts higher circulating testosterone in older men: the health in men study. Clin Endocrinol2009;70:455–63.doi:10.1111/j.1365-2265.2008.03372.x
68.
NieschlagE, LammersU, FreischemCW, . Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab1982;55:676–81.doi:10.1210/jcem-55-4-676
69.
WuFCW, TajarA, BeynonJM, . Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med2010;363:123–35.doi:10.1056/NEJMoa0911101
70.
GrayA, FeldmanHA, McKinlayJB, . Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging Study*. J Clin Endocrinol Metab1991;73:1016–25.doi:10.1210/jcem-73-5-1016
71.
FeldmanHA, LongcopeC, DerbyCA, . Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab2002;87:589–98.doi:10.1210/jcem.87.2.8201
72.
TravisonTG, VesperHW, OrwollE, . Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. J Clin Endocrinol Metab2017;102:1161–73.doi:10.1210/jc.2016-2935
73.
WellD, YangH, HouseniM, . Age-Related structural and metabolic changes in the pelvic reproductive end organs. Semin Nucl Med2007;37:173–84.doi:10.1053/j.semnuclmed.2007.01.004
74.
MahmoudAM, GoemaereS, El-GaremY, . Testicular volume in relation to hormonal indices of gonadal function in community-dwelling elderly men. J Clin Endocrinol Metab2003;88:179–84.doi:10.1210/jc.2002-020408
SasanoN, IchijoS. Vascular patterns of the human testis with special reference to its senile changes. Tohoku J Exp Med1969;99:269–80.doi:10.1620/tjem.99.269
77.
KiddSA, EskenaziB, WyrobekAJ. Effects of male age on semen quality and fertility: a review of the literature. Fertil Steril2001;75:237–48.doi:10.1016/S0015-0282(00)01679-4
78.
BegueriaR, GarciaD, ObradorsA, . Paternal age and assisted reproductive outcomes in ICSI donor oocytes: is there an effect of older fathers?Hum Reprod2014;29:2114–22.doi:10.1093/humrep/deu189
79.
DakouaneM, BicchierayL, BergereM, . A histomorphometric and cytogenetic study of testis from men 29–102 years old. Fertil Steril2005;83:923–8.doi:10.1016/j.fertnstert.2004.12.005
80.
JohnsonL, PettyCS, NeavesWB. Influence of age on sperm production and testicular weights in men. Reproduction1984;70:211–8.doi:10.1530/jrf.0.0700211
81.
DhindsaS, MillerMG, McWhirterCL, . Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care2010;33:1186–92.doi:10.2337/dc09-1649
82.
BaworM, BamiH, DennisBB, . Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend2015;149:1–9.doi:10.1016/j.drugalcdep.2015.01.038
GrossmannM, HoermannR, GaniL, . Low testosterone levels as an independent predictor of mortality in men with chronic liver disease. Clin Endocrinol2012;77:323–8.doi:10.1111/j.1365-2265.2012.04347.x
85.
KhuranaKK, NavaneethanSD, ArrigainS, . Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis2014;64:367–74.doi:10.1053/j.ajkd.2014.03.010
PakpoorJ, GoldacreR, GoldacreMJ. Associations between clinically diagnosed testicular hypofunction and systemic lupus erythematosus: a record linkage study. Clin Rheumatol2018;37:559–62.doi:10.1007/s10067-017-3873-5
88.
KollerMD. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis2004;63:1677–80.doi:10.1136/ard.2003.018325
89.
GarciaJM, LiH, MannD, . Hypogonadism in male patients with cancer. Cancer2006;106:2583–91.doi:10.1002/cncr.21889
90.
MylonakisE, KoutkiaP, GrinspoonS. Diagnosis and treatment of androgen deficiency in human immunodeficiency Virus–Infected men and women. Clin Infect Dis2001;33:857–64.doi:10.1086/322695
91.
WangC, ChanV, TseTF, . Effect of acute myocardial infarction on pituitary-testicular function. Clin Endocrinol1978;9:249–53.doi:10.1111/j.1365-2265.1978.tb02207.x
92.
RingJ, HeineltM, SharmaS, . Oxandrolone in the treatment of burn injuries: a systematic review and meta-analysis. Journal of Burn Care Research2019;154.doi:10.1093/jbcr/irz155
93.
BallingerAB, AND SavageMO, SandersonIANR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res2003;53:205–10.doi:10.1203/00006450-200302000-00002
94.
NiermanDM, MechanickJI. Hypotestosteronemia in chronically critically ill men. Crit Care Med1999;27:2418–21.doi:10.1097/00003246-199911000-00016
95.
LuppaP, MunkerR, NagelD, . Serum androgens in intensive-care patients: correlations with clinical findings. Clin Endocrinol1991;34:305–10.doi:10.1111/j.1365-2265.1991.tb03771.x
96.
DaniellHW, LentzR, MazerNA. Open-Label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain2006;7:200–10.doi:10.1016/j.jpain.2005.10.009
97.
van StaaTP, LeufkensHGM, CooperC, . The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int2002;13:777–87.doi:10.1007/s001980200108
98.
DongQ, HawkerF, McWilliamD, . Circulating immunoreactive inhibin and testosterone levels in men with critical illness. Clin Endocrinol1992;36:399–404.doi:10.1111/j.1365-2265.1992.tb01466.x
99.
FcW, TajarA, PyeSR, . Hypothalamic-Pituitary-Testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J Clin Endocrinol Metab2008;93:2737–45.
100.
GrossmannM. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab2011;96:2341–53.doi:10.1210/jc.2011-0118
101.
StanikS, DornfeldLP, MaxwellMH, . The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab1981;53:828–32.doi:10.1210/jcem-53-4-828
102.
DhindsaS, FurlanettoR, VoraM, . Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care2011;34:1854–9.doi:10.2337/dc11-0208
103.
YeapBB, AlfonsoH, ChubbSAP, . Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men. J Clin Endocrinol Metab2012;97:4030–9.doi:10.1210/jc.2012-2265
104.
TajarA, FortiG, O'NeillTW, . Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab2010;95:1810–8.doi:10.1210/jc.2009-1796
105.
GhanimH, DhindsaS, AbuayshehS, . Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone. Eur J Endocrinol2018;62:277–83.doi:10.1530/EJE-17-0673
106.
GrossmannM, ThomasMC, PanagiotopoulosS, . Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab2008;93:1834–40.doi:10.1210/jc.2007-2177
107.
KapoorD, AldredH, ClarkS, . Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care2007;30:911–7.doi:10.2337/dc06-1426
108.
ChandelA, DhindsaS, TopiwalaS, . Testosterone concentration in young patients with diabetes. Diabetes Care2008;31:2013–7.doi:10.2337/dc08-0851
109.
MogriM, DhindsaS, QuattrinT, . Testosterone concentrations in young pubertal and post-pubertal obese males. Clin Endocrinol2013;78:593–9.doi:10.1111/cen.12018
110.
VandewalleS, TaesY, FiersT, . Sex steroids in relation to sexual and skeletal maturation in obese male adolescents. J Clin Endocrinol Metab2014;99:2977–85.doi:10.1210/jc.2014-1452
111.
TomarR, DhindsaS, ChaudhuriA, . Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care2006;29:1120–2.doi:10.2337/dc06-0197
112.
Escobar-MorrealeHF, SantacruzE, Luque-RamírezM, . Prevalence of ‘obesity-associated gonadal dysfunction’ in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update2017;23:390–408.doi:10.1093/humupd/dmx012
113.
KapoorD, ChannerKS, JonesTH. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res2008;5:135–7.doi:10.3132/dvdr.2008.022
114.
GeorgeJT, VeldhuisJD, Tena-SempereM, . Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol2013;79:100–4.doi:10.1111/cen.12103
115.
CastellanoJM, NavarroVM, RoaJ, . Alterations in hypothalamic KiSS-1 system in experimental diabetes: early changes and functional consequences. Endocrinology2009;150:784–94.doi:10.1210/en.2008-0849
116.
ShoelsonSE, LeeJ, GoldfineAB. Inflammation and insulin resistance. J Clin Invest2006;116:1793–801.doi:10.1172/JCI29069
117.
KahnSE, HullRL, UtzschneiderKM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature2006;444:840–6.doi:10.1038/nature05482
118.
Martos-MorenoG.Á., ChowenJA, ArgenteJ. Metabolic signals in human puberty: effects of over and undernutrition. Mol Cell Endocrinol2010;324:70–81.doi:10.1016/j.mce.2009.12.017
119.
KapraraA, HuhtaniemiIT. The hypothalamus-pituitary-gonad axis: tales of mice and men. Metabolism2018;86:3–17.doi:10.1016/j.metabol.2017.11.018
120.
HarterCJL, KavanaghGS, SmithJT. The role of kisspeptin neurons in reproduction and metabolism. J Endocrinol2018;238:R173–83.doi:10.1530/JOE-18-0108
121.
ForbesS, LiXF, Kinsey-JonesJ, . Effects of ghrelin on kisspeptin mRNA expression in the hypothalamic medial preoptic area and pulsatile luteinising hormone secretion in the female rat. Neurosci Lett2009;460:143–7.doi:10.1016/j.neulet.2009.05.060
122.
WahabF, AtikaB, UllahF, . Metabolic impact on the hypothalamic Kisspeptin-Kiss1r signaling pathway. Front Endocrinol2018;9:123.doi:10.3389/fendo.2018.00123
123.
SarchielliE, ComeglioP, SqueccoR, . Tumor necrosis factor-α impairs kisspeptin signaling in human gonadotropin-releasing hormone primary neurons. J Clin Endocrinol Metab2017;102:46–56.doi:10.1210/jc.2016-2115
124.
RoaJ, BarrosoA, Ruiz-PinoF, . Metabolic regulation of female puberty via hypothalamic AMPK–kisspeptin signaling. Proc Natl Acad Sci U S A2018;115:E10758–67.doi:10.1073/pnas.1802053115
125.
AnderssonU, FilipssonK, AbbottCR, . Amp-Activated protein kinase plays a role in the control of food intake. J Biol Chem2004;279:12005–8.doi:10.1074/jbc. C300557200
126.
MinokoshiY, AlquierT, FurukawaN, . Amp-Kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature2004;428:569–74.doi:10.1038/nature02440
127.
WongHK, HoermannR, GrossmannM. Reversible male hypogonadotropic hypogonadism due to energy deficit. Clin Endocrinol2019;52.doi:10.1111/cen.13973
128.
FarooqiIS, MatareseG, LordGM, . Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest2002;110:1093–103.doi:10.1172/JCI0215693
SmithJT, AcohidoBV, CliftonDK, . Kiss-1 neurones are direct targets for leptin in the ob/ob mouse. J Neuroendocrinol2006;18:298–303.doi:10.1111/j.1365-2826.2006.01417.x
131.
YangY, AtasoyD, SuHH, . Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop. Cell2011;146:992–1003.doi:10.1016/j.cell.2011.07.039
132.
BackholerK, SmithJT, RaoA, . Kisspeptin cells in the ewe brain respond to leptin and communicate with neuropeptide Y and proopiomelanocortin cells. Endocrinology2010;151:2233–43.doi:10.1210/en.2009-1190
133.
DonatoJ, FrazãoR, FrazãoR, . Leptin's effect on puberty in mice is relayed by the ventral premammillary nucleus and does not require signaling in Kiss1 neurons. J Clin Invest2011;121:355–68.doi:10.1172/JCI45106
134.
CravoRM, FrazaoR, PerelloM, . Leptin signaling in KISS1 neurons arises after pubertal development. PLoS One2013;8:e58698.doi:10.1371/journal.pone.0058698
135.
PusztaiP, SarmanB, RuzicskaE, . Ghrelin: a new peptide regulating the neurohormonal system, energy homeostasis and glucose metabolism. Diabetes Metab Res Rev2008;24:343–52.doi:10.1002/dmrr.830
136.
Tena-SempereM, GhrelinT-SM. Ghrelin, the gonadal axis and the onset of puberty. Endocr Dev2013;25:69–82.doi:10.1159/000346055
137.
SliwowskaJH, FerganiC, GawałekM, . Insulin: its role in the central control of reproduction. Physiol Behav2014;133:197–206.doi:10.1016/j.physbeh.2014.05.021
138.
KullmannS, HeniM, HallschmidM, . Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev2016;96:1169–209.doi:10.1152/physrev.00032.2015
139.
OsbornO, OlefskyJM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med2012;18:363–74.doi:10.1038/nm.2627
140.
BruningJC. Role of brain insulin receptor in control of body weight and reproduction. Science2000;289:2122–5.doi:10.1126/science.289.5487.2122
141.
QiuX, DowlingAR, MarinoJS, . Delayed Puberty but Normal Fertility in Mice With Selective Deletion of Insulin Receptors From Kiss1 Cells. Endocrinology2013;154:1337–48.doi:10.1210/en.2012-2056
142.
ManaserhIH, ChikkamenahalliL, RaviS, . Ablating astrocyte insulin receptors leads to delayed puberty and hypogonadism in mice. PLoS Biol2019;17:e3000189.doi:10.1371/journal.pbio.3000189
143.
ClasadonteJ, PoulainP, HanchateNK, . Prostaglandin E2 release from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor activation. Proc Natl Acad Sci U S A2011;108:16104–9.doi:10.1073/pnas.1107533108
144.
AchariAE, JainSK, AdiponectinJSK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci2017;18. doi:doi:10.3390/ijms18061321. [Epub ahead of print: 21 Jun 2017].
145.
KadowakiT, YamauchiT, Okada-IwabuM, . Adiponectin and its receptors: implications for obesity-associated diseases and longevity. Lancet Diabetes Endocrinol2014;2:8–9.doi:10.1016/S2213-8587(13)70120-7
146.
YamauchiT, KamonJ, WakiH, . The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med2001;7:941–6.doi:10.1038/90984
147.
WenJ-P, LvW-S, YangJ, . Globular adiponectin inhibits GnRH secretion from GT1 hypothalamic GnRH neurons by induction of hyperpolarization of membrane potential. Biochem Biophys Res Commun2008;371:756–61.doi:10.1016/j.bbrc.2008.04.146
148.
RakA, MelloukN, FromentP, . Adiponectin and resistin: potential metabolic signals affecting hypothalamo-pituitary gonadal axis in females and males of different species. Reproduction2017;153:R215–26.doi:10.1530/REP-17-0002
149.
TurnbullAV, RivierC. Inhibition of Gonadotropin-Induced Testosterone Secretion by the Intracerebroventricular Injection of Interleukin-1β in the Male rat. Endocrinology1997;138:1008–13.doi:10.1210/endo.138.3.5019
150.
TsigosC, PapanicolaouDA, DefensorR, . Dose effects of recombinant human lnterleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology1997;66:54–62.doi:10.1159/000127219
151.
IgazP, SalviR, ReyJ-P, . Effects of cytokines on gonadotropin-releasing hormone (GnRH) gene expression in primary hypothalamic neurons and in GnRH neurons immortalized conditionally. Endocrinology2006;147:1037–43.doi:10.1210/en.2005-0729
152.
NettleshipJ, PughP, ChannerK, . Inverse relationship between serum levels of interleukin-1β and testosterone in men with stable coronary artery disease. Horm Metab Res2007;39:366–71.doi:10.1055/s-2007-976543
153.
BobjerJ, KatrinakiM, TsatsanisC, . Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One2013;8:e61466.doi:10.1371/journal.pone.0061466
154.
VeldhuisJ, YangR, RoelfsemaF, . Proinflammatory cytokine infusion attenuates LH's feedforward on testosterone secretion: modulation by age. J Clin Endocrinol Metab2016;101:539–49.doi:10.1210/jc.2015-3611
155.
JasoniCL, TodmanMG, HanS-K, . Expression of mRNAs encoding receptors that mediate stress signals in gonadotropin-releasing hormone neurons of the mouse. Neuroendocrinology2005;82:320–8.doi:10.1159/000093155
156.
LainezNM, JonakCR, NairMG, . Diet-Induced obesity elicits macrophage infiltration and reduction in spine density in the hypothalami of male but not female mice. Front Immunol1992;2018.
157.
WatanobeH, HayakawaY. Hypothalamic interleukin-1β and tumor necrosis factor-α, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology2003;144:4868–75.doi:10.1210/en.2003-0644
158.
RivestS, LeeS, AttardiB, . The chronic intracerebroventricular infusion of interleukin-1 beta alters the activity of the hypothalamic-pituitary-gonadal axis of cycling rats. I. Effect on LHRH and gonadotropin biosynthesis and secretion. Endocrinology1993;133:2424–30.doi:10.1210/endo.133.6.8243260
159.
NamKN, MounierA, WolfeCM, . Effect of high fat diet on phenotype, brain transcriptome and lipidome in Alzheimer's model mice. Sci Rep2017;7:4307.doi:10.1038/s41598-017-04412-2
160.
AraujoAB, EscheGR, KupelianV, . Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab2007;92:4241–7.doi:10.1210/jc.2007-1245
161.
AraujoAB, O'DonnellAB, BrambillaDJ, . Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab2004;89:5920–6.doi:10.1210/jc.2003-031719
162.
BojesenA, JuulS, GravholtCH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab2003;88:622–6.doi:10.1210/jc.2002-021491
163.
MorrisJK, AlbermanE, ScottC, . Is the prevalence of Klinefelter syndrome increasing?Eur J Hum Genet2008;16:163–70.doi:10.1038/sj.ejhg.5201956
164.
BoisenE. Testicular size and shape of 47,XYY and 47,XXY men in a double-blind, double-matched population survey. Am J Hum Genet1979;31:697–703.
165.
BrintonLA, CarreonJD, GierachGL, . Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat2010;119:185–92.doi:10.1007/s10549-009-0379-0
166.
MoralesA, BebbRA, ManjooP, . Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. Can Med Assoc J2015;187:1369–77.doi:10.1503/cmaj.150033
167.
HeinemannLAJ, ZimmermannT, VermeulenA, . A new ‘aging males’ symptoms’ rating scale. The Aging Male1999;2:105–14.doi:10.3109/13685539909003173
168.
LiuZY, ZhouRY, LuX, . Identification of late-onset hypogonadism in middle-aged and elderly men from a community of China. Asian J Androl2016;18:747–53.
169.
LiuZ, LiuJ, ShiX, . Comparing calculated free testosterone with total testosterone for screening and diagnosing late-onset hypogonadism in aged males: a cross-sectional study. J Clin Lab Anal2017;31:e22073.doi:10.1002/jcla.22073
170.
ChuehK-S, HuangS-P, LeeY-C, . The comparison of the aging male symptoms (ams) scale and androgen deficiency in the aging male (ADAM) questionnaire to detect androgen deficiency in middle-aged men. J Androl2012;33:817–23.doi:10.2164/jandrol.111.015628
171.
AraujoAB, DixonJM, SuarezEA, . Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab2011;96:3007–19.doi:10.1210/jc.2011-1137
172.
HaringR, VolzkeH, StevelingA, . Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J2010;31:1494–501.doi:10.1093/eurheartj/ehq009
173.
LaughlinGA, Barrett-ConnorE, BergstromJ. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab2008;93:68–75.doi:10.1210/jc.2007-1792
174.
MuraleedharanV, MarshH, KapoorD, . Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol2013;169:725–33.doi:10.1530/EJE-13-0321
175.
ShoresMM, SmithNL, ForsbergCW, . Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab2012;97:2050–8.doi:10.1210/jc.2011-2591
176.
BremnerWJ, VitielloMV, PrinzPN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal Men*. J Clin Endocrinol Metab1983;56:1278–81.doi:10.1210/jcem-56-6-1278
177.
BrambillaDJ, O'DonnellAB, MatsumotoAM, . Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol2007;67:853–62.doi:10.1111/j.1365-2265.2007.02976.x
178.
SikarisK, McLachlanRI, KazlauskasR, . Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab2005;90:5928–36.doi:10.1210/jc.2005-0962
179.
WangC, CatlinDH, DemersLM, . Measurement of Total Serum Testosterone in Adult Men: Comparison of Current Laboratory Methods Versus Liquid Chromatography-Tandem Mass Spectrometry. J Clin Endocrinol Metab2004;89:534–43.doi:10.1210/jc.2003-031287
180.
RosnerW, AuchusRJ, AzzizR, . Utility, limitations, and pitfalls in measuring testosterone: an endocrine Society position statement. J Clin Endocrinol Metab2007;92:405–13.doi:10.1210/jc.2006-1864
181.
OrwollE, BlankJB, Barrett-ConnorE, . Design and baseline characteristics of the osteoporotic fractures in men (MROS) study — a large observational study of the determinants of fracture in older men. Contemp Clin Trials2005;26:569–85.doi:10.1016/j.cct.2005.05.006
182.
BhasinS, PencinaM, JasujaGK, . Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab2011;96:2430–9.doi:10.1210/jc.2010-3012
183.
LapauwBM, TaesY, BogaertV, . Serum estradiol is associated with volumetric BMD and modulates the impact of physical activity on bone size at the age of peak bone mass: a study in healthy male siblings. J Bone Miner Res2009;24:1075–85.doi:10.1359/jbmr.081260
184.
MoralesA, CollierCP, ClarkAF. A critical appraisal of accuracy and cost of laboratory methodologies for the diagnosis of hypogonadism: the role of free testosterone assays. Can J Urol2012;19:6314–8.
185.
VermeulenA, VerdonckL, KaufmanJM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab1999;84:3666–72.doi:10.1210/jcem.84.10.6079
186.
SödergardR, BäckströmT, ShanbhagV, . Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem1982;16:801–10.doi:10.1016/0022-4731(82)90038-3
187.
HuangG, BasariaS, TravisonTG, . Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause2014;21:612–23.
188.
SpitzerM, BasariaS, TravisonTG, . Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction. Ann Intern Med2012;157:681–91.doi:10.7326/0003-4819-157-10-201211200-00004
189.
MarksLS, MazerNA, MostaghelE, . Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. JAMA2006;296:2351–61.doi:10.1001/jama.296.19.2351
190.
PageST, LinDW, MostaghelEA, . Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin of Metab2006;91:3850–6.doi:10.1210/jc.2006-0968
191.
PageST, LinDW, MostaghelEA, . Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab2011;96:430–7.doi:10.1210/jc.2010-1865
192.
KarpasAE, MatsumotoAM, PaulsenCA, . Elevated serum follicle-stimulating hormone levels in men with normal seminal fluid analyses. Fertil Steril1983;39:333–6.
193.
DalviM, WalkerBR, StrachanMWJ, . The prevalence of structural pituitary abnormalities by MRI scanning in men presenting with isolated hypogonadotrophic hypogonadism. Clin Endocrinol2016;84:858–61.doi:10.1111/cen.13015
194.
NianY, DingM, HuS, . Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: a meta-analysis of randomized controlled trials. Andrologia2017;49:e12630.doi:10.1111/and.12630
195.
PonceOJ, Spencer-BonillaG, Alvarez-VillalobosN, . The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Endocrinol Metab2018;1754. doi:doi:10.1210/jc.2018-00404
196.
ThompsonIM. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA2005;294:66–70.doi:10.1001/jama.294.1.66
197.
SnyderPJ, EllenbergSS, CunninghamGR, . The testosterone trials: seven coordinated trials of testosterone treatment in elderly men. Clinical Trials2014;11:362–75.doi:10.1177/1740774514524032
198.
DerogatisLR. The derogatis interview for sexual functioning (DISF/DISF-SR): an introductory report. J Sex Marital Ther1997;23:291–304.doi:10.1080/00926239708403933
199.
LeeKK, BermanN, AlexanderGM, . A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl2003;24:688–98.doi:10.1002/j.1939-4640.2003.tb02728.x
200.
WangC, Stephens-ShieldsAJ, DeRogatisLR, . Validity and clinically meaningful changes in the psychosexual daily questionnaire and Derogatis interview for sexual function assessment: results from the testosterone trials. J Sex Med2018;15:997–1009.doi:10.1016/j.jsxm.2018.05.008
201.
CunninghamGR, Stephens-ShieldsAJ, RosenRC, . Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab2016;101:3096–104.doi:10.1210/jc.2016-1645
202.
BjornerJB, WallensteinGV, MartinMC, . Interpreting score differences in the SF-36 vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin2007;23:731–9.doi:10.1185/030079907X178757
203.
LöweB, UnützerJ, CallahanCM, . Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care2004;42:1194–201.doi:10.1097/00005650-200412000-00006
204.
NordinÅsa, TaftC, Lundgren-NilssonÅsa, . Minimal important differences for fatigue patient reported outcome measures—a systematic review. BMC Med Res Methodol2016;16:62.doi:10.1186/s12874-016-0167-6
205.
ResnickSM, MatsumotoAM, Stephens-ShieldsAJ. Cognitive function after testosterone treatment. JAMA2017;317:2335–6.doi:10.1001/jama.2017.5245
206.
RoyCN, SnyderPJ, Stephens-ShieldsAJ, . Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med2017;177:480–90.doi:10.1001/jamainternmed.2016.9540
207.
BudoffMJ, EllenbergSS, LewisCE, . Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA2017;317:708–16.doi:10.1001/jama.2016.21043
208.
SnyderPJ, KopperdahlDL, Stephens-ShieldsAJ, . Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. JAMA Intern Med2017;177:471–9.doi:10.1001/jamainternmed.2016.9539
209.
Fernández-BalsellsMM, MuradMH, LaneM, . Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab2010;95:2560–75.doi:10.1210/jc.2009-2575
210.
CorbettaS, MuzzaM, AvaglianoL, . Gonadal structures in a fetus with complete androgen insensitivity syndrome and persistent Müllerian derivatives: comparison with normal fetal development. Fertil Steril2011;95:1119.e9–1114.doi:10.1016/j.fertnstert.2010.09.028
211.
Imperato-McGinleyJ, GautierT, ZirinskyK, . Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab1992;75:1022–6.doi:10.1210/jcem.75.4.1400866
212.
WilsonJD, RoehrbornC. Long-Term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts. J Clin Endocrinol Metab1999;84:4324–31.doi:10.1210/jcem.84.12.6206
213.
BehreHM, BohmeyerJ, NieschlagE. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol1994;40:341–9.doi:10.1111/j.1365-2265.1994.tb03929.x
214.
ShaneyfeltT, HuseinR, BubleyG, . Hormonal predictors of prostate cancer: a meta-analysis. JCO2000;18:847–53.doi:10.1200/JCO.2000.18.4.847
215.
PierorazioPM, FerrucciL, KettermannA, . Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore longitudinal study of aging. BJU Int2010;105:824–9.doi:10.1111/j.1464-410X.2009.08853.x
216.
GannPH, HennekensCH, MaJ, . Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst1996;88:1118–26.doi:10.1093/jnci/88.16.1118
217.
MorgentalerA, ConnersW. Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations. Asian J Androl2015;17:206–11.doi:10.4103/1008-682X.148067
218.
MeariniL, ZucchiA, NunziE, . Low serum testosterone levels are predictive of prostate cancer. World J Urol2013;31:247–52.doi:10.1007/s00345-011-0793-x
219.
ShinBS, HwangEC, ImCM, . Is a decreased serum testosterone level a risk factor for prostate cancer? a cohort study of Korean men. Korean J Urol2010;51:819–23.doi:10.4111/kju.2010.51.12.819
220.
RoddamAW, AllenNE, ApplebyP, . Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst2008;100:170–83.doi:10.1093/jnci/djm323
221.
MullerRL, GerberL, MoreiraDM, . Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol2012;62:757–64.doi:10.1016/j.eururo.2012.05.025
222.
RohrmannS, NelsonWG, RifaiN, . Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab2007;92:2519–25.doi:10.1210/jc.2007-0028
223.
CalofOM, SinghAB, LeeML, . Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci2005;60:1451–7.doi:10.1093/gerona/60.11.1451
224.
HaddadRM, KennedyCC, CaplesSM, . Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clinic Proc2007;82:29–39.doi:10.1016/S0025-6196(11)60964-6
225.
DobsAS, MeikleAW, ArverS, . Efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab1999;84:3469–78.
226.
BraekkanSK, MathiesenEB, NjolstadI, . Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica2010;95:270–5.doi:10.3324/haematol.2009.008417
227.
GlueckCJ, PrinceM, PatelN, . Thrombophilia in 67 patients with thrombotic events after starting testosterone therapy. Clin Appl Thromb Hemost2016;22:548–53.doi:10.1177/1076029615619486
228.
CoronaG, RastrelliG, MonamiM, . Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol2011;165:687–701.doi:10.1530/EJE-11-0447
229.
KhawKT, DowsettM, FolkerdE, . Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation2007;116:2694–701.
230.
CoronaG, MonamiM, BoddiV, . Low testosterone is associated with an increased risk of Mace lethality in subjects with erectile dysfunction. J Sex Med2010;7:1557–64.doi:10.1111/j.1743-6109.2009.01690.x
231.
BasariaS, CovielloAD, TravisonTG, . Adverse events associated with testosterone administration. N Engl J Med2010;363:109–22.doi:10.1056/NEJMoa1000485
232.
VigenR, O'DonnellCI, BarónAE, . Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA2013;310:1829–36.doi:10.1001/jama.2013.280386
233.
MorgentalerA, LunenfeldB. Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male2014;17:63–5.doi:10.3109/13685538.2014.913413
234.
MorgentalerA, TraishA, KackerR. Deaths and cardiovascular events in men receiving testosterone. JAMA2014;311:961–2.doi:10.1001/jama.2014.392
235.
FinkleWD, GreenlandS, RidgewayGK, . Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One2014;9:e85805.doi:10.1371/journal.pone.0085805
236.
SeftelAD. Re: Testosterone Products: Drug Safety Communication - FDA Cautions about Using Testosterone Products for Low Testosterone due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and Stroke. J Urol2015;194:759–60.doi:10.1016/j.juro.2015.06.058
237.
SharmaR, OniOA, GuptaK, . Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J2015;36:2706–15.doi:10.1093/eurheartj/ehv346
238.
EisenbergML, LiS, HerderD, . Testosterone therapy and mortality risk. Int J Impot Res2015;27:46–8.doi:10.1038/ijir.2014.29
239.
BaillargeonJ, UrbanRJ, KuoY-F, . Risk of myocardial infarction in older men receiving testosterone therapy. Annals of Pharmacotherapy2014;48:1138–44.doi:10.1177/1060028014539918
240.
MaggiM, WuFCW, JonesTH, . Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the registry of hypogonadism in men (RHYME). Int J Clin Pract2016;70:843–52.doi:10.1111/ijcp.12876
241.
AlexanderGC, IyerG, LucasE, . Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med2017;130:293–305.doi:10.1016/j.amjmed.2016.09.017
242.
AndersonJL, MayHT, LappéDL, . Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. Am J Cardiol2016;117:794–9.doi:10.1016/j.amjcard.2015.11.063
243.
CoronaG, MaseroliE, RastrelliG, . Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf2014;13:1327–51.doi:10.1517/14740338.2014.950653
244.
TanRS, CookKR, ReillyWG. Myocardial infarction and stroke risk in young healthy men treated with injectable testosterone. Int J Endocrinol2015;2015:1–8.doi:10.1155/2015/970750
245.
TraishAM, HaiderA, HaiderKS, . Long-Term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther2017;22:414–33.doi:10.1177/1074248417691136
246.
WallisCJD, LoK, LeeY, . Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol2016;4:498–506.doi:10.1016/S2213-8587(16)00112-1
247.
CheethamTC, AnJ, JacobsenSJ, . Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med2017;177:491–9.doi:10.1001/jamainternmed.2016.9546
248.
OniOA, SharmaR, ChenG, . Normalization of testosterone levels after testosterone replacement therapy is not associated with reduced myocardial infarction in smokers. Mayo Clin Proc2017;1:57–66.doi:10.1016/j.mayocpiqo.2017.05.003
249.
SharmaR, OniOA, ChenG, . Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: a retrospective cohort study of the Veterans administration database. Chest2016;150:563–71.
